Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Richard on +44 1494 818057 or richard@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Richard Swann
Recruitment Consultant
richard@zenopa.com
+44 1494 818057

Testimonials
When I came to Zenopa I wasn't looking for just any job. Zenopa always respected that and have persevered to find me a job that fitted with my career and my preferences.
Candidate, 2011

Actavis launches Irinotecan in UK

15 July 2009 00:00 in Pharmacy Supplier News


Actavis has announced the launch of the therapy Irinotecan in the UK.

In a statement, the organisation said that the treatment, which is the generic equivalent of Pfizer's Camptosar, is also available in Austria, France, Germany, the Netherlands and Sweden as of today.

The drug is available in two different vial sizes - 40mg/2ml and 100mg/5ml - and is used for the management of patients with metastatic carcinoma of the rectum or colon.

Actavis stated that the patents for the drug expired on July 12th and 13th, adding that it is the first company to market it in all six of the aforementioned EU countries.

The company added: "Actavis and its third-party sales division, Medis, have now launched Irinotecan in more than 20 countries. Irinotecan Actavis is produced by Actavis Romania."

Earlier this year, the company announced that its over-the-counter drug Clamelle was given the Nicholas Hall European New Product of the Year Award, which is presented to celebrate innovative and successful product launches.

Other news stories from 15/07/2009

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd